Percutaneous absorption of clobetasol propionate from novel ointment and cream formulations

The percutaneous absorption of clobetasol propionate from Dermovate® (Glaxo) ointment and cream was modified by reformulation. Propylene glycol, acting as vehicle for the steroid, was removed and replaced by di‐n‐butyl adipate. This significantly reduced the brightness of vasoconstriction over 24 h, after application of the new formulations to the forearms of healthy volunteers; the areas of vasoconstriction were slightly increased. Plasma cortisol levels were not affected by 12 nightly applications of 15 g of each of the new formulations, whereas this regimen produced marked depression of plasma cortisol levels when Dermovate was used. Circulating levels of clobetasol propionate were considerably lower over a 96‐h period after applications of 30 g of the new formulations in comparison with the marketed formulations. The percutaneous absorption of clobetasol propionate was therefore considerably reduced by reformulation. The implications for therapy are discussed.